Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices">megaphone.fm/adchoices</a>

Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit megaphone.fm/adchoices

Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="noopener noreferrer">megaphone.fm/adchoices</a>

Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap

Eyewire News: The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources.

News

Business News

Eyewire News: The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources.

Eyewire News:&nbsp;The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources.

Share Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap

Sign up to save your podcasts

Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap

Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap